

July 26, 2025

To	To
The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051
Code: 540222	Code: LAURUSLABS

Dear Sir / Madam,

Sub: Newspaper Publication pertaining to Financial Results for the quarter ended June 30, 2025

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of the newspaper advertisement pertaining to Financial Results of the Company for the quarter ended June 30, 2025.

The advertisements were published in "Business Standard" (English) and "Prajasakti" (Telugu) on July 26, 2025.

This is for your information and records.

Yours faithfully,

For **Laurus Labs Limited**

G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District – 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com


CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad – 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

 SOLARA Active Pharma Sciences		SOLARA ACTIVE PHARMA SCIENCES LIMITED CIN: L24230MH2017PLC291636 Regd. Office: 9th Floor, "Cyber One", Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703 Tel: +91-22-2789 2924 Corporate Office: TICEL BIO PARK, 6th floor Module No. 601, 602, 603, Phase II - CSIR Road, Taramani, Chennai, Tamil Nadu - 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in, www.solara.co.in			
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025 (Rs. in Crores except per share data)					
Sl. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous Financial Year ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		UNAUDITED	(Refer Note 5)	UNAUDITED	AUDITED
Continuing operations:					
1	Total income from operations	319.15	273.01	363.49	1,283.76
2	Net Profit for the period before tax (before exceptional items)	10.52	(2.10)	(13.46)	0.54
3	Net Profit for the period before tax (after exceptional items)	10.52	(2.10)	(13.46)	0.54
4	Net Profit for the period after tax	10.52	(2.10)	(13.46)	0.54
5	Other Comprehensive Income for the period	(0.01)	(0.62)	(0.01)	0.98
6	Total Comprehensive Income for the period (4 + 5)	10.51	(2.72)	(13.47)	1.52
7	Equity Share Capital	44.34	40.25	40.21	40.25
8	Other Equity				1,053.99
9	Earnings Per Share (of Rs. 10/- each) (for continuing operations) -				
	Basic (Rs.)	2.46	(0.93)	(3.50)	0.14
	Diluted (Rs.)	2.46	(0.93)	(3.50)	0.14
Notes:					
1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites of the National Stock Exchange of India Limited (www.nseindia.com), BSE Limited (www.bseindia.com) and at the Company's website (www.solara.co.in)					
2 The above consolidated financial results of Solara Active Pharma Sciences Limited ("the Parent" or the Company" and its subsidiaries (together referred to as "the group") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on July 25, 2025. The results for the quarter ended June 30, 2025 has been reviewed by Deloitte Haskins & Sells LLP, the statutory auditors of the Company. The statutory auditors of the Company have expressed an unmodified conclusion in respect of limited review for the quarter ended June 30, 2025.					
3 The Parent, vide its letter of offer dated May 09, 2024 offered upto 1,19,98,755 partly paid equity shares of face value of Rs. 10/- each at a price of Rs. 375 per Equity share (including Share premium of Rs. 365 per Equity share) for an amount aggregating Rs. 449.95 crores to the existing share holders of the Parent on right basis in the ratio of One Equity share for every three Equity shares held by the Equity shareholders on the record date i.e May 15, 2024. Rights issue has been done in accordance with Section 62(1)(a) of the Companies Act and other applicable laws. The Parent has allotted 1,19,98,755 Nos. of partly paid up equity shares on June 19, 2024. On March 26, 2025, the Company, approved the Rights Issue First Call of Rs. 131.25 per Rights Share (Rs. 3.50 face value and Rs. 127.75 Share premium) for 1,19,98,755 partly paid Rights Shares, as per the Letter of Offer dated May 09, 2024. The First Call payment window was open from April 16, 2025 to April 30, 2025. The Rights Issue Subcommittee on May 06, 2025, took note of receipt of First call money amounting Rs.149.49 Crores and approved conversion of 1,13,89,767 partly paid shares of Rs. 3.5 per share to partly paid of Rs. 7 per share. Out of net proceeds from First Call money, Rs. 115.00 crores is used against repayment of borrowings, Rs.23.27 crores towards general corporate purposes in line with terms of utilization mentioned in letter of offer.					
4 The Board of Directors of the Parent at its meeting held on January 24, 2025 had discussed a proposal to explore 'demerger of the CRAMS and Polymers business into an independent listed entity' and granted in-principle approval for the same. Pursuant to this, the Parent incorporated a wholly owned subsidiary, Synthix Global Pharma Solutions Limited, on April 29, 2025.					
5 The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and year to date figures up to third quarter of the financial year then ended as disclosed in the financial results for the year ended March 31, 2025.					
 For and on behalf of board Sd/- Sandeep Shashikantha Rao MD & CEO DIN: 10838251					
Place : Bengaluru Date : July 25, 2025					

 Extracts of Statement of Consolidated Financial Results for the quarter ended 30 June, 2025				
(₹ in crore)				
Particulars	Quarter ended 30 June, 2025 (Unaudited)	Quarter ended 31 March, 2025 (Audited)	Quarter ended 30 June, 2024 (Unaudited)	Year ended 31 March, 2025 (Audited)
	Not annualised			Annualised
1. Revenue from continuing operations	3,719	3,509	3,789	14,887
2. Profit/(loss) from continuing operations before exceptional items, share of profit/(loss) of joint ventures and associate and tax	318	(61)	215	492
3. Profit/(loss) from continuing operations after exceptional items, before share of profit/(loss) of joint ventures and associate and tax	318	(116)	215	367
4. Profit/(loss) from continuing operations before tax	360	(92)	269	521
5. Profit/(loss) from continuing operations after tax	316	(67)	175	354
6. Profit/(loss) from discontinued operations after tax	-	18	15	33
7. Profit/(loss) for the period (5 + 6)	316	(49)	190	387
8. Total comprehensive income for the period	1,037	(79)	(178)	(114)
9. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255
10. Other equity and Non-controlling interests				22,246
11. Securities premium account	1,259	1,259	1,259	1,259
12. Net worth	23,215	22,501	22,514	22,501
13. Outstanding debt	7,126	7,072	6,376	7,072
14. Earnings per share				
- Basic and Diluted (for continuing operations) in ₹	9.89	(2.90)	5.30	7.93
- Basic and Diluted (for discontinued operations) in ₹	-	0.71	0.59	1.30
- Basic and Diluted (for continuing and discontinued operations) in ₹	9.89	(2.19)	5.89	9.23
15. Debt equity ratio (no. of times)	0.31	0.31	0.28	0.31
16. Debt service coverage ratio (no. of times)	3.88	2.84	3.35	2.71
17. Interest service coverage ratio (no. of times)	4.41	2.39	4.32	3.47

Extracts of Statement of Standalone Audited Financial Results for the quarter ended 30 June, 2025				
Particulars	Quarter ended 30 June, 2025	Quarter ended 31 March, 2025	Quarter ended 30 June, 2024	Year ended 31 March, 2025
	Not annualised			Annualised
1. Revenue from continuing operations	1,169	1,219	1,047	4,441
2. Profit from continuing operations before tax	332	102	322	624
3. Profit from continuing operations after tax	307	97	256	524
4. Profit from discontinued operations after tax	-	18	15	33
5. Profit for the period (3 + 4)	307	115	271	557
6. Total comprehensive income for the period	1,060	(18)	(120)	(149)
7. Paid-up equity share capital (Face value: ₹ 10 per share)	255	255	255	255
8. Other equity				17,939
9. Securities premium account	1,258	1,258	1,258	1,258
10. Net worth	18,974	18,194	18,223	18,194
11. Outstanding debt	1,979	2,261	574	2,261
12. Earnings per share				
- Basic and Diluted (for continuing operations) in ₹	12.05	3.80	10.05	20.57
- Basic and Diluted (for discontinued operations) in ₹	-	0.71	0.59	1.30
- Basic and Diluted (for continuing and discontinued operations) in ₹	12.05	4.51	10.64	21.87
13. Debt equity ratio (no. of times)	0.10	0.12	0.03	0.12
14. Debt service coverage ratio (no. of times)	19.29	5.23	27.20	13.86
15. Interest service coverage ratio (no. of times)	5.40	4.69	18.08	5.68

Notes:

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 25 July, 2025.

2. The above is an extract of the detailed format of the Unaudited Consolidated and Audited Standalone financial results for the quarter ended 30 June, 2025 filed with the Stock Exchanges under Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Unaudited Consolidated and Audited Standalone financial results for the quarter ended 30 June, 2025 is available on the Stock Exchange websites (www.nseindia.com and www.bseindia.com) and on the Company's website (www.tatachemicals.com). The same can be accessed by scanning the QR code provided below.

For and on behalf of the Board of

TATA CHEMICALS LIMITED

R. Mukundan
Managing Director and CEO

TATA CHEMICALS LIMITED

Regd. Office : Bombay House, 24 Homi Mody Street, Fort, Mumbai - 400 001.
Tel: +91 22 66658282 Website: www.tatachemicals.com
CIN:- L24239MH1939PLC002893 Email: investors@tatachemicals.com

